









Markets
/
Stocks
/
nasdaq-evgn
/

Evogene Ltd

EVGN



View Detailed Chart

1.030USD

-0.020-1.90%

Close 12/26, 16:00（ET）Quotes delayed by 15 min

8.98MMarket Cap

LossP/E TTM



Evogene Ltd

1.030

-0.020-1.90%

Overview Company Financials Analysis

Overview

Company

Financials

Analysis

Intraday

30m

Today

-1.90%

5 Days

+0.99%

1 Month

-9.25%

6 Months

-19.53%

Year to Date

-44.92%

1 Year

-39.05%

View Detailed Chart

TradingKey Stock Score of Evogene Ltd

Currency: USD Updated: 2025-12-26

Key Insights

Evogene Ltd's fundamentals are relatively healthy, and its growth potential is significant.Its valuation is considered fairly valued, ranking 120/404 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 2.50.In the medium term, the stock price is expected to trend down.Despite an average stock market performance over the past month, the company shows strong technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Evogene Ltd's Score

Industry at a Glance

Industry Ranking

120 / 404

Overall Ranking

237 / 4563

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Analyst Rating

Based on 1 analysts

Buy

Current Rating

2.500

Target Price

+117.39%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Evogene Ltd Highlights

StrengthsRisks

Evogene Ltd is an Israel-based company, engaged in leveraging computational biology to design products for life-science-based industries including human health, agriculture, and industrial applications. Leveraging Big Data and Artificial Intelligence while incorporating a deep understanding of biology, Evogene established its technology, the Computational Predictive Biology (CPB) platform, to computationally design microbes, small molecules and genes as the core components for life-science products. Evogene holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 408.12% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 8.51M.

Undervalued

The company’s latest PE is -7.54, at a low 3-year percentile range.

Held by James Simons

Star Investor James Simons holds 0.00 shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.82.